Nanoviriricides, Inc. announced that he had received authorization from the National Ethics Committee of the Democratic Republic of Congo to launch a phase II clinical trial request for the NV-387. This broad -spectrum antiviral medication targets MPOX disease caused by HMPXV infection. This is a crucial step for the next marketing authorization requests from the DRC Ministry of Public Health.
The study aims to assess the safety and efficiency of the NV-387, already recognized for its effectiveness in animal models against viruses such as flu and coronavirus. It should be noted that no current drug effectively treats the infection with the HMPXV. Nanoviricides highlights the unique mechanism of the NV-387, which imitates host cells to trap and destroy viruses, and could revolutionize antiviral treatment.
The test will be carried out at the Kinshasa University Hospital, under the direction of a principal researcher. This initiative meets the growing need for more robust antiviral defenses, highlighted by recent MPOX epidemics in Africa.
R. P.
 | Approval of the Phase II clinical trial of NV-387 of Nanoviriricides in the DRC){kind=link}